(TECH) Bio-Techne - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09073M1045
Stock: Reagents, Instruments, Services, Assays, Kits
Total Rating 46
Risk 93
Buy Signal -0.64
| Risk 5d forecast | |
|---|---|
| Volatility | 41.5% |
| Relative Tail Risk | -6.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.06 |
| Alpha | -41.20 |
| Character TTM | |
|---|---|
| Beta | 1.271 |
| Beta Downside | 1.371 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.32% |
| CAGR/Max DD | -0.20 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 101.6793
Description: TECH Bio-Techne March 04, 2026
Bio-Techne Corporation (TECH) develops and sells life science reagents, instruments, and services globally. Its operations span research, diagnostics, and bioprocessing markets. The companys business model focuses on providing essential tools for biological discovery and medical applications.
The Protein Sciences segment offers biological reagents like cytokines and antibodies, crucial for cell and gene therapy research. This segment also provides proteomic analytical tools, including automated western blot and ELISA systems, which are standard in protein quantification.
The Diagnostics and Spatial Biology segment develops diagnostic products, including controls, calibrators, and assays for regulated markets. This includes exosome-based molecular diagnostics and advanced in-situ hybridization assays for tissue analysis. The company also supplies genetic and oncology kits, and instruments for hematology and blood chemistry, serving both research and clinical applications. The life sciences tools and services sector is characterized by continuous innovation and a strong demand from pharmaceutical and biotechnology companies.
To deepen your understanding of TECHs market position, consider exploring its intellectual property and recent product launches on ValueRay.
Headlines to watch out for
- Research and development spending impacts reagent demand
- Biopharmaceutical industry growth drives protein sciences revenue
- Diagnostic product sales influenced by healthcare regulations
- Cell and gene therapy market expansion boosts instrument demand
- Global economic conditions affect research funding availability
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 81.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.68 > 1.0 |
| NWC/Revenue: 40.89% < 20% (prev 39.58%; Δ 1.31% < -1%) |
| CFO/TA 0.10 > 3% & CFO 249.3m > Net Income 81.1m |
| Net Debt (178.0m) to EBITDA (227.2m): 0.78 < 3 |
| Current Ratio: 4.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (157.0m) vs 12m ago -2.26% < -2% |
| Gross Margin: 65.22% > 18% (prev 0.66%; Δ 6.46k% > 0.5%) |
| Asset Turnover: 46.81% > 50% (prev 44.79%; Δ 2.03% > 0%) |
| Interest Coverage Ratio: 13.29 > 6 (EBITDA TTM 227.2m / Interest Expense TTM 9.29m) |
Altman Z'' 5.19
| A: 0.20 (Total Current Assets 637.4m - Total Current Liabilities 140.4m) / Total Assets 2.52b |
| B: 0.44 (Retained Earnings 1.11b / Total Assets 2.52b) |
| C: 0.05 (EBIT TTM 123.5m / Avg Total Assets 2.60b) |
| D: 2.04 (Book Value of Equity 1.05b / Total Liabilities 511.7m) |
| Altman-Z'' Score: 5.19 = AAA |
Beneish M -3.22
| DSRI: 0.83 (Receivables 184.6m/217.9m, Revenue 1.22b/1.20b) |
| GMI: 1.01 (GM 65.22% / 65.62%) |
| AQI: 0.99 (AQ_t 0.63 / AQ_t-1 0.64) |
| SGI: 1.02 (Revenue 1.22b / 1.20b) |
| TATA: -0.07 (NI 81.1m - CFO 249.3m) / TA 2.52b) |
| Beneish M-Score: -3.22 (Cap -4..+1) = AA |
What is the price of TECH shares?
As of March 15, 2026, the stock is trading at USD 53.62 with a total of 1,928,381 shares traded.
Over the past week, the price has changed by -5.64%, over one month by -15.15%, over three months by -13.24% and over the past year by -14.58%.
Over the past week, the price has changed by -5.64%, over one month by -15.15%, over three months by -13.24% and over the past year by -14.58%.
Is TECH a buy, sell or hold?
Bio-Techne has received a consensus analysts rating of 4.13.
Therefore, it is recommended to buy TECH.
- StrongBuy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TECH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 75.3 | 40.3% |
| Analysts Target Price | 75.3 | 40.3% |
TECH Fundamental Data Overview March 15, 2026
P/E Trailing = 101.6793
P/E Forward = 25.1889
P/S = 6.936
P/B = 4.1926
P/EG = 0.6877
Revenue TTM = 1.22b USD
EBIT TTM = 123.5m USD
EBITDA TTM = 227.2m USD
Long Term Debt = 260.0m USD (from longTermDebt, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 350.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 178.0m USD (from netDebt column, last quarter)
Enterprise Value = 8.61b USD (8.43b + Debt 350.9m - CCE 172.9m)
Interest Coverage Ratio = 13.29 (Ebit TTM 123.5m / Interest Expense TTM 9.29m)
EV/FCF = 38.60x (Enterprise Value 8.61b / FCF TTM 223.0m)
FCF Yield = 2.59% (FCF TTM 223.0m / Enterprise Value 8.61b)
FCF Margin = 18.35% (FCF TTM 223.0m / Revenue TTM 1.22b)
Net Margin = 6.67% (Net Income TTM 81.1m / Revenue TTM 1.22b)
Gross Margin = 65.22% ((Revenue TTM 1.22b - Cost of Revenue TTM 422.8m) / Revenue TTM)
Gross Margin QoQ = 64.65% (prev 65.65%)
Tobins Q-Ratio = 3.41 (Enterprise Value 8.61b / Total Assets 2.52b)
Interest Expense / Debt = 0.62% (Interest Expense 2.17m / Debt 350.9m)
Taxrate = 25.16% (12.8m / 50.8m)
NOPAT = 92.4m (EBIT 123.5m * (1 - 25.16%))
Current Ratio = 4.54 (Total Current Assets 637.4m / Total Current Liabilities 140.4m)
Debt / Equity = 0.17 (Debt 350.9m / totalStockholderEquity, last quarter 2.01b)
Debt / EBITDA = 0.78 (Net Debt 178.0m / EBITDA 227.2m)
Debt / FCF = 0.80 (Net Debt 178.0m / FCF TTM 223.0m)
Total Stockholder Equity = 1.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.12% (Net Income 81.1m / Total Assets 2.52b)
RoE = 4.10% (Net Income TTM 81.1m / Total Stockholder Equity 1.98b)
RoCE = 5.52% (EBIT 123.5m / Capital Employed (Equity 1.98b + L.T.Debt 260.0m))
RoIC = 4.04% (NOPAT 92.4m / Invested Capital 2.29b)
WACC = 10.19% (E(8.43b)/V(8.78b) * Re(10.60%) + D(350.9m)/V(8.78b) * Rd(0.62%) * (1-Tc(0.25)))
Discount Rate = 10.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.96%
[DCF] Terminal Value 68.97% ; FCFF base≈235.5m ; Y1≈217.7m ; Y5≈196.8m
[DCF] Fair Price = 14.70 (EV 2.48b - Net Debt 178.0m = Equity 2.30b / Shares 156.5m; r=10.19% [WACC]; 5y FCF grow -9.56% → 2.90% )
EPS Correlation: -23.36 | EPS CAGR: -4.19% | SUE: 1.29 | # QB: 1
Revenue Correlation: 50.42 | Revenue CAGR: 0.50% | SUE: 0.78 | # QB: 0
EPS current Year (2026-06-30): EPS=1.98 | Chg7d=-0.003 | Chg30d=+0.013 | Revisions Net=+2 | Growth EPS=+3.2% | Growth Revenue=+0.5%
EPS next Year (2027-06-30): EPS=2.17 | Chg7d=-0.003 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=+9.4% | Growth Revenue=+6.3%
[Analyst] Revisions Ratio: +0.20 (6 Up / 4 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 9.6% (Discount Rate 10.6% - Earnings Yield 1.0%)
[Growth] Growth Spread = -3.3% (Analyst 6.3% - Implied 9.6%)
P/E Forward = 25.1889
P/S = 6.936
P/B = 4.1926
P/EG = 0.6877
Revenue TTM = 1.22b USD
EBIT TTM = 123.5m USD
EBITDA TTM = 227.2m USD
Long Term Debt = 260.0m USD (from longTermDebt, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 350.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 178.0m USD (from netDebt column, last quarter)
Enterprise Value = 8.61b USD (8.43b + Debt 350.9m - CCE 172.9m)
Interest Coverage Ratio = 13.29 (Ebit TTM 123.5m / Interest Expense TTM 9.29m)
EV/FCF = 38.60x (Enterprise Value 8.61b / FCF TTM 223.0m)
FCF Yield = 2.59% (FCF TTM 223.0m / Enterprise Value 8.61b)
FCF Margin = 18.35% (FCF TTM 223.0m / Revenue TTM 1.22b)
Net Margin = 6.67% (Net Income TTM 81.1m / Revenue TTM 1.22b)
Gross Margin = 65.22% ((Revenue TTM 1.22b - Cost of Revenue TTM 422.8m) / Revenue TTM)
Gross Margin QoQ = 64.65% (prev 65.65%)
Tobins Q-Ratio = 3.41 (Enterprise Value 8.61b / Total Assets 2.52b)
Interest Expense / Debt = 0.62% (Interest Expense 2.17m / Debt 350.9m)
Taxrate = 25.16% (12.8m / 50.8m)
NOPAT = 92.4m (EBIT 123.5m * (1 - 25.16%))
Current Ratio = 4.54 (Total Current Assets 637.4m / Total Current Liabilities 140.4m)
Debt / Equity = 0.17 (Debt 350.9m / totalStockholderEquity, last quarter 2.01b)
Debt / EBITDA = 0.78 (Net Debt 178.0m / EBITDA 227.2m)
Debt / FCF = 0.80 (Net Debt 178.0m / FCF TTM 223.0m)
Total Stockholder Equity = 1.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.12% (Net Income 81.1m / Total Assets 2.52b)
RoE = 4.10% (Net Income TTM 81.1m / Total Stockholder Equity 1.98b)
RoCE = 5.52% (EBIT 123.5m / Capital Employed (Equity 1.98b + L.T.Debt 260.0m))
RoIC = 4.04% (NOPAT 92.4m / Invested Capital 2.29b)
WACC = 10.19% (E(8.43b)/V(8.78b) * Re(10.60%) + D(350.9m)/V(8.78b) * Rd(0.62%) * (1-Tc(0.25)))
Discount Rate = 10.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.96%
[DCF] Terminal Value 68.97% ; FCFF base≈235.5m ; Y1≈217.7m ; Y5≈196.8m
[DCF] Fair Price = 14.70 (EV 2.48b - Net Debt 178.0m = Equity 2.30b / Shares 156.5m; r=10.19% [WACC]; 5y FCF grow -9.56% → 2.90% )
EPS Correlation: -23.36 | EPS CAGR: -4.19% | SUE: 1.29 | # QB: 1
Revenue Correlation: 50.42 | Revenue CAGR: 0.50% | SUE: 0.78 | # QB: 0
EPS current Year (2026-06-30): EPS=1.98 | Chg7d=-0.003 | Chg30d=+0.013 | Revisions Net=+2 | Growth EPS=+3.2% | Growth Revenue=+0.5%
EPS next Year (2027-06-30): EPS=2.17 | Chg7d=-0.003 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=+9.4% | Growth Revenue=+6.3%
[Analyst] Revisions Ratio: +0.20 (6 Up / 4 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 9.6% (Discount Rate 10.6% - Earnings Yield 1.0%)
[Growth] Growth Spread = -3.3% (Analyst 6.3% - Implied 9.6%)